Encorafenib + Binimetinib Displays Promising Safety, Efficacy Signals in BRAFV600E/K–Mutated Melanoma

Key Points:

Treatment with a combined BRAF/MEK–targeted approach previously demonstrated success in stage III/IV melanoma, leading Columbus-AD trial investigators to evaluate encorafenib and binimetinib in stage IIB/C, BRAFV600E/K–mutated disease.
When new immunotherapy agents began to demonstrate efficacy, the placebo control in the Columbus-AD trial was deemed unethical, and trial recruitment was halted.
In spite of the comparative lack of data and shorter follow-up, Columbus-AD showed that encorafenib/binimetinib is a safe and feasible combination, with survival curves trending toward improvement.

You must be logged in to post a comment.